Observational Study
Copyright ©The Author(s) 2017.
World J Diabetes. Jun 15, 2017; 8(6): 286-296
Published online Jun 15, 2017. doi: 10.4239/wjd.v8.i6.286
Table 4 Results of logistic regression models assessing the association between duration of statin use and cognitive impairment in middle-aged adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study
Variables in ModelCognitive impairment OR (95%CI) P value
Model 1Never used statinsReferent group
1-6 yr statins3.16 (0.93-10.72), P = 0.064
7-12 yr statins4.84 (1.63-14.44), P = 0.005
Model 2Never used statinsReferent group
1-6 yr statins2.86 (0.83-9.86), P = 0.095
7-12 yr statins4.26 (1.40-13.00), P = 0.011
Average LDLc1.01 (0.99-1.03), P = 0.24
Model 3Never used statinsReferent group
1-6 yr statins3.29 (0.95-11.40), P = 0.061
7-12 yr statins4.13 (1.35-12.60), P = 0.013
CAD2.88 (0.88-9.44), P = 0.081
Model 4Never used statinsReferent group
1-6 yr statins3.14 (0.93-10.64), P = 0.066
7-12 yr statins4.95 (1.65-14.82), P = 0.004
Apo E4 allele0.73 (0.26-2.02), P = 0.55
Model 5Never used statinsReferent group
1-6 yr statins2.90 (0.82-10.29), P = 0.099
7-12 yr statins3.69 (1.17-11.68), P = 0.026
Average LDLc1.01 (0.99-1.03), P = 0.24
CAD2.72 (0.81-9.13), P = 0.11
Apo E4 allele0.75 (0.26-2.15), P = 0.59
Statin use groups: Never used n = 51; 1-6 years n = 25; 7+ years n = 32. Binary outcome: Cognitive impairment present/absent. Model 1: Statin use groups, controlling for age and education; Model 2: Model 1, further controlling for average long-term LDLc (1986-1988 through 2010-2013); Model 3: Model 1, further controlling for prevalent coronary artery disease (CAD); Model 4: Model 1, further controlling for Apo E4 allele status (24, 34, or 44); Model 5: Model 1, further controlling for LDLc, CAD, and Apo E4 allele. LDLc: Low density lipoprotein cholesterol.